<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076192</url>
  </required_header>
  <id_info>
    <org_study_id>P11-067</org_study_id>
    <nct_id>NCT01076192</nct_id>
  </id_info>
  <brief_title>Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)</brief_title>
  <acronym>PROMISE</acronym>
  <official_title>Post-authorization, Observational Study to Evaluate the Effectiveness of Adalimumab (HUMIRA®) on Moderate-severe Psoriasis Under Conditions of Routine Clinical Practice in Spain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IMS Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of adalimumab as used
      in routine clinical practice in adult patients with moderate to severe chronic plaque
      psoriasis in Spain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROMISE is a 2 year post-authorization study of patients taking adalimumab for Psoriasis.
      Patients who volunteer to participate will be asked to provide information about their
      medical history and experiences with adalimumab. No study specific testing will be performed.
      Patients will be asked to provide data on their experiences with adalimumab approximately
      every 6 months, or as determined by the study doctor. No drug will be provided as a result of
      participation in the registry. All treatment decisions are independent of participation in
      the registry. A total of 547 subjects were enrolled: 532 in the ITT population were analyzed
      for efficacy (excluding 15 for lack of follow-up visits (n=8), non-fulfillment of the
      criteria of moderate to severe PS (n=6) and failure to initiate treatment at the baseline
      visit (n=1)); 542 were analyzed for safety (excluding 5 due to lack of evaluable safety
      data).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
    <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A lower (and negative) value of change indicates an increase in the severity of the psoriasis, while a positive value indicates an improvement in the severity of the PS. Missing data were imputed using last observation carried forward (LOCF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Reduction in PASI Score of at Least 50% (PASI 50)</measure>
    <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
    <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Reduction in PASI Score of at Least 75% (PASI 75)</measure>
    <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
    <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Reduction in PASI Score of at Least 90% (PASI 90)</measure>
    <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
    <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Reduction in PASI Score of 100% (PASI 100)</measure>
    <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
    <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 100 response is the percentage of participants who achieved a 100% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Body Surface Area (BSA) Affected</measure>
    <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
    <description>Body Surface Area (BSA) affected or the psoriasis area is determined by the direct calculation of the affected body surface area. This determination was used to evaluate the effectiveness of the treatment during each of the study visits. The change was calculated by deducting the final score from the baseline score. Increased scores correspond to reduction of severity and reduction of BSA. Missing data were imputed using LOCF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Improvement From Baseline in Physician's Global Assessment (PGA)</measure>
    <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
    <description>The PGA was used to measure participants' disease status at the time of assessment. This tool is a horizontal visual analogue 6-point scale measuring the degree of overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe). The percentage of patients who showed an improvement from baseline in their PGA scores is presented. Missing data were imputed using LOCF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline and every 6 months up to month 24</time_frame>
    <description>DLQI is a self-administered Health Related Quality of Life (HRQL) questionnaire specifically for patients with dermatological diseases, adapted and validated in the Spanish population. It consists of 10 items with a Likert response scale for 4 categories and uses a 7 day time reference. It generates a global score that ranges from 0 (better HRQL) to 30 (worse HRQL) points. Change in DLQI was calculated by deducting the final score from the baseline score. Missing data were imputed using LOCF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EuroQol Quality of Life Questionnaire (EQ-5D) Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline and every 6 months up to month 24</time_frame>
    <description>The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where increased scores correspond to better HRQL. 0 is the 'worst imaginable health state' and 100 is the 'best imaginable health state'. Change in EQ-5D VAS score was calculated by deducting the final score from the baseline score. Increased scores correspond to better health state. Missing data were imputed using LOCF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Percentage of Lost Productivity Assessed Using Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP)</measure>
    <time_frame>Baseline and every 6 months up to month 24</time_frame>
    <description>WPAI-SHP is a questionnaire used to evaluate lost productivity. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. Increased (positive) scores correspond to a reduction in the percentage of lost work productivity. Missing data were imputed using LOCF. n=the number of participants with data at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>From time of informed consent to the final visit after 2 years of observation</time_frame>
    <description>AESIs are adverse events of special interest, including infection, neoplasm, lupus-like, demyelinating disease, serious hepatic and/or haematological event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>From time of informed consent to the final visit after 2 years of observation</time_frame>
    <description>SAEs are adverse event with any of the following severity criteria: Potentially fatal/endangers life, Hospitalisation or prolonging of hospitalisation, a medically important event that requires medical or surgical intervention to prevent a serious outcome, Disability or persistent incapacitation, death, congenital anomalies and/or miscarriage or abortion.
See the Reported Adverse Events Section for more details.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">547</enrollment>
  <condition>Moderate-to-severe Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Moderate-to-severe chronic plaque psoriasis</arm_group_label>
    <description>Participants with moderate-to-severe chronic plaque psoriasis treated with adalimumab in routine clinical practice</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with moderate-to-severe chronic plaque psoriasis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient 18 years of age or older.

          -  Patient diagnosed with moderate to severe chronic plaque PS beginning treatment with
             adalimumab in accordance with the authorized conditions of use.

          -  Patient gives informed consent in writing.

        Exclusion Criteria:

          -  Patients who cannot be treated in accordance with the local product label

          -  Patient participating or going to participate in a clinical trial during the study
             follow-up

          -  Patient with difficulties for adequately reading, understanding and completing a
             questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Sancho Sanchez, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Abbvie Farmaceutica, S.L.U. Spain</affiliation>
  </overall_official>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <results_first_submitted>September 25, 2015</results_first_submitted>
  <results_first_submitted_qc>December 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2016</results_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate Psoriasis</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Severe Psoriasis</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <keyword>Clinical practice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 547 subjects were enrolled: 532 in the ITT population were analyzed for efficacy (excluding 15 for lack of follow-up visits (n=8), non-fulfillment of the criteria of moderate to severe PS (n=6) and failure to initiate treatment at the baseline visit (n=1)); 542 were analyzed for safety (excluding 5 due to lack of evaluable safety data).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
          <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="547"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analyses accounts for Intention to treat (ITT) population (all participants who received at least 1 dose of study drug and had at least 1 follow-up visit).</population>
      <group_list>
        <group group_id="B1">
          <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
          <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="532"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.48" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI)</title>
        <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A lower (and negative) value of change indicates an increase in the severity of the psoriasis, while a positive value indicates an improvement in the severity of the PS. Missing data were imputed using last observation carried forward (LOCF).</description>
        <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
        <population>Efficacy analyses included all participants who received at least 1 dose of adalimumab and had at least one follow-up visit (ITT) with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI)</title>
          <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A lower (and negative) value of change indicates an increase in the severity of the psoriasis, while a positive value indicates an improvement in the severity of the PS. Missing data were imputed using last observation carried forward (LOCF).</description>
          <population>Efficacy analyses included all participants who received at least 1 dose of adalimumab and had at least one follow-up visit (ITT) with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.39" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.30" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.52" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.32" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.21" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.93" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.91" spread="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Reduction in PASI Score of at Least 50% (PASI 50)</title>
        <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
        <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
        <population>Efficacy analyses included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Reduction in PASI Score of at Least 50% (PASI 50)</title>
          <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
          <population>Efficacy analyses included ITT population with evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Reduction in PASI Score of at Least 75% (PASI 75)</title>
        <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
        <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
        <population>Efficacy analyses included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Reduction in PASI Score of at Least 75% (PASI 75)</title>
          <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
          <population>Efficacy analyses included ITT population with evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Dermatology Life Quality Index (DLQI)</title>
        <description>DLQI is a self-administered Health Related Quality of Life (HRQL) questionnaire specifically for patients with dermatological diseases, adapted and validated in the Spanish population. It consists of 10 items with a Likert response scale for 4 categories and uses a 7 day time reference. It generates a global score that ranges from 0 (better HRQL) to 30 (worse HRQL) points. Change in DLQI was calculated by deducting the final score from the baseline score. Missing data were imputed using LOCF.</description>
        <time_frame>Baseline and every 6 months up to month 24</time_frame>
        <population>Efficacy analyses included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Dermatology Life Quality Index (DLQI)</title>
          <description>DLQI is a self-administered Health Related Quality of Life (HRQL) questionnaire specifically for patients with dermatological diseases, adapted and validated in the Spanish population. It consists of 10 items with a Likert response scale for 4 categories and uses a 7 day time reference. It generates a global score that ranges from 0 (better HRQL) to 30 (worse HRQL) points. Change in DLQI was calculated by deducting the final score from the baseline score. Missing data were imputed using LOCF.</description>
          <population>Efficacy analyses included ITT population with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EuroQol Quality of Life Questionnaire (EQ-5D) Visual Analogue Scale (VAS)</title>
        <description>The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where increased scores correspond to better HRQL. 0 is the 'worst imaginable health state' and 100 is the 'best imaginable health state'. Change in EQ-5D VAS score was calculated by deducting the final score from the baseline score. Increased scores correspond to better health state. Missing data were imputed using LOCF.</description>
        <time_frame>Baseline and every 6 months up to month 24</time_frame>
        <population>Analysis included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EuroQol Quality of Life Questionnaire (EQ-5D) Visual Analogue Scale (VAS)</title>
          <description>The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where increased scores correspond to better HRQL. 0 is the 'worst imaginable health state' and 100 is the 'best imaginable health state'. Change in EQ-5D VAS score was calculated by deducting the final score from the baseline score. Increased scores correspond to better health state. Missing data were imputed using LOCF.</description>
          <population>Analysis included ITT population with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="453"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.79" spread="21.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.27" spread="22.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.91" spread="23.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.71" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Percentage of Lost Productivity Assessed Using Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP)</title>
        <description>WPAI-SHP is a questionnaire used to evaluate lost productivity. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. Increased (positive) scores correspond to a reduction in the percentage of lost work productivity. Missing data were imputed using LOCF. n=the number of participants with data at each time point.</description>
        <time_frame>Baseline and every 6 months up to month 24</time_frame>
        <population>Analysis included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Percentage of Lost Productivity Assessed Using Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP)</title>
          <description>WPAI-SHP is a questionnaire used to evaluate lost productivity. The scores on the WPAI questionnaire are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Change in WPAI-SHP was calculated by deducting the final score from the baseline score. Increased (positive) scores correspond to a reduction in the percentage of lost work productivity. Missing data were imputed using LOCF. n=the number of participants with data at each time point.</description>
          <population>Analysis included ITT population with evaluable data.</population>
          <units>units on a scale (a derived score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.61" spread="24.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.86" spread="24.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.63" spread="25.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.89" spread="21.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events of Special Interest (AESIs)</title>
        <description>AESIs are adverse events of special interest, including infection, neoplasm, lupus-like, demyelinating disease, serious hepatic and/or haematological event.</description>
        <time_frame>From time of informed consent to the final visit after 2 years of observation</time_frame>
        <population>Analysis included safety analysis population i.e., all participants who received at least 1 dose of adalimumab with evaluable safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Special Interest (AESIs)</title>
          <description>AESIs are adverse events of special interest, including infection, neoplasm, lupus-like, demyelinating disease, serious hepatic and/or haematological event.</description>
          <population>Analysis included safety analysis population i.e., all participants who received at least 1 dose of adalimumab with evaluable safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebrovascular accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematological event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lupus-like syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Reduction in PASI Score of at Least 90% (PASI 90)</title>
        <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
        <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
        <population>Efficacy analyses included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Reduction in PASI Score of at Least 90% (PASI 90)</title>
          <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
          <population>Efficacy analyses included ITT population with evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Reduction in PASI Score of 100% (PASI 100)</title>
        <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 100 response is the percentage of participants who achieved a 100% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
        <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
        <population>Efficacy analyses included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Reduction in PASI Score of 100% (PASI 100)</title>
          <description>PASI is a measurement of the severity of psoriasis. It is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI 100 response is the percentage of participants who achieved a 100% reduction (improvement) from baseline in PASI score. Missing data were imputed using LOCF.</description>
          <population>Efficacy analyses included ITT population with evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Body Surface Area (BSA) Affected</title>
        <description>Body Surface Area (BSA) affected or the psoriasis area is determined by the direct calculation of the affected body surface area. This determination was used to evaluate the effectiveness of the treatment during each of the study visits. The change was calculated by deducting the final score from the baseline score. Increased scores correspond to reduction of severity and reduction of BSA. Missing data were imputed using LOCF.</description>
        <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
        <population>Efficacy analyses included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Body Surface Area (BSA) Affected</title>
          <description>Body Surface Area (BSA) affected or the psoriasis area is determined by the direct calculation of the affected body surface area. This determination was used to evaluate the effectiveness of the treatment during each of the study visits. The change was calculated by deducting the final score from the baseline score. Increased scores correspond to reduction of severity and reduction of BSA. Missing data were imputed using LOCF.</description>
          <population>Efficacy analyses included ITT population with evaluable data.</population>
          <units>percentage of body surface area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.24" spread="15.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.86" spread="18.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.86" spread="19.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.75" spread="19.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.62" spread="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.04" spread="19.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.18" spread="20.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Improvement From Baseline in Physician's Global Assessment (PGA)</title>
        <description>The PGA was used to measure participants’ disease status at the time of assessment. This tool is a horizontal visual analogue 6-point scale measuring the degree of overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe). The percentage of patients who showed an improvement from baseline in their PGA scores is presented. Missing data were imputed using LOCF.</description>
        <time_frame>Baseline, month 1 and every 3 months the first year and every 6 months up to month 24</time_frame>
        <population>Efficacy analyses included ITT population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement From Baseline in Physician's Global Assessment (PGA)</title>
          <description>The PGA was used to measure participants’ disease status at the time of assessment. This tool is a horizontal visual analogue 6-point scale measuring the degree of overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe). The percentage of patients who showed an improvement from baseline in their PGA scores is presented. Missing data were imputed using LOCF.</description>
          <population>Efficacy analyses included ITT population with evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>SAEs are adverse event with any of the following severity criteria: Potentially fatal/endangers life, Hospitalisation or prolonging of hospitalisation, a medically important event that requires medical or surgical intervention to prevent a serious outcome, Disability or persistent incapacitation, death, congenital anomalies and/or miscarriage or abortion.
See the Reported Adverse Events Section for more details.</description>
        <time_frame>From time of informed consent to the final visit after 2 years of observation</time_frame>
        <population>Analysis included safety analysis population i.e., all participants who received at least 1 dose of adalimumab with evaluable safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
            <description>Participants with moderate-to-severe chronic plaque psoriasis treated with adalimumab in routine clinical practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>SAEs are adverse event with any of the following severity criteria: Potentially fatal/endangers life, Hospitalisation or prolonging of hospitalisation, a medically important event that requires medical or surgical intervention to prevent a serious outcome, Disability or persistent incapacitation, death, congenital anomalies and/or miscarriage or abortion.
See the Reported Adverse Events Section for more details.</description>
          <population>Analysis included safety analysis population i.e., all participants who received at least 1 dose of adalimumab with evaluable safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from start of study (Month 0) through month 24 following the start of treatment with adalimumab.</time_frame>
      <desc>Analysis included safety analysis population i.e., all participants who received at least 1 dose of adalimumab with evaluable safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Moderate-to-severe Chronic Plaque Psoriasis</title>
          <description>Participants with moderate-to-severe chronic plaque psoriasis treated with Humira® in routine clinical practice</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Ferropenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>cervical lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>class iii heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>unstable angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>non-specific tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>complete auriculoventricular blockage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>acute myocardial infarction of the inferoposterior wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo syndromes and non-specific labyrinth disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage of the digestive tract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>acute pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>acute gastric ulcer with haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>chrohn ileocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>oesophageal erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>multiorganic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>non-specific chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>lupus-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tuberculous meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>community-acquired pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>sepsis caused by methicillin-resistant staphylococcus aureus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>infection by cytomegalovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>erysipela</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>infection by Escherichia coli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>enterococcus bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>septicaemia by candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>motorcycle accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>dislocated hip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>torn anterior cruciate ligament</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>normal nuclear magnetic resonance imaging</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>steroid-induced diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>psoriatic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>spondylarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>psoriatic arthopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>septic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelodisplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>basocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>squamous cell carcinoma of the lungs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>clear cell carcinoma of the kidneys</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>astrocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>invasive breast duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>sebaceous cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>malignant neoplasms of the sigmoid colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>adenocarcinoma of the breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>hepatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>adenocarcinoma of the colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>bronchial carcinoma, stage iv</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>chronic myelogenous leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>carcinoma with unknown primary tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>urothelial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>lung metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>bone metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>subarachnoid haemorrhage after traumatic injury without mention of open intracraneal wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>neurosensory hypoacusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>unwanted pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>miscarriage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>state of confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ureterohydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ovarian benign germ cell teratoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>tonsil hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>allergic bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>acute respiratory insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>exacerbation of copd</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>outbreak of psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>suppurative hydradenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>worsening of psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>arthrodesis of the toe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>cardiac ablation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>radical prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>abortion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>bariatric surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="314" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal erythrocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Cervical lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Ferropenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Macrocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Megaloblastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Chest pain during exertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Coronary artery calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Decompensated heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Paroxistic tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic nodular chondrodermatitis helicis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Earache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Inflammation of the middle ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Meniere’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Sudden deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Excessive tearing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Eye discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Glare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Posterior detachment of the vitreous humour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pseudopterigion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Terrien’s marginal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abdominal pain not otherwise specified</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Acute gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Epigastralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Functional dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increase in size of submaxillar gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Irritable bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Irritation of the palate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Leukoplakia of the oral mucosa (incl. tongue)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Loss of dental piece</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pain in molars</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Painful tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Rectorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Tarry stool</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Tooth sensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Worsening of crohn’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>General discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Ineffective drug</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Itching in the injection zone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Low-grade fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Oedema of the face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Oedema of the feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Oedema of the leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Oedema of the limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Oedema of the lower limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pain at the puncture location</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pain in the injection zone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Paradoxical reaction to a drug</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Post-surgical pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Reaction at injection site</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Worsening of the disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hypersensitivity at injection site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliar colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Drug-induced liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Allergy to insect stings</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Lupus-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Rheumatic polymyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abscess on a limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abscess on the back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Acute ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Acute pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Athlete’s foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Axillary abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Boil</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Bronchiolitis caused by respiratory syncytial virus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Common cold syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Condylomata</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Condylomata acuminata</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dental infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Face cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Foot cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Furunculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Gastritis caused by helicobacter pylori</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Genital wart</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Infection by blastocystis hominis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Infection of upper airways not otherwise specified</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Inguinal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Labial herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Leg cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Mandibular osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Non-specific chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Non-specific middle ear function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Viral infection not otherwise specified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Onphalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Ophthalmological herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Outer ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Penile candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pharyngitis not otherwise specified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pharyngoamygdalitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Purulent secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Streptococcus tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Unspecified intestinal parasitosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Urinary tract infection by Escherichia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Verruca vulgaris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Viral gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Viriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Warts (viral)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dental fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Falls</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Fractured metatarsal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Intoxication by immunosuppressants</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Trauma injuries of limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Traumatic injuries of the lumbosacral plexus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abnormal cholesterol in blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abnormal gamma-glutamyl transferase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abnormal glucose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abnormal glutamate-pyruvate transaminase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abnormal uric acid in blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abnormal triglycerides</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Abnormal triglycerides in blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Average corpuscle volume</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Decreased platelets</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Determination of C1Q</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated alpha-fetoprotein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated amylase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated average corpuscle volume</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated ferritin in plasma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated glutamate oxaloacetate transaminase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated glutamate-pyruvate transaminase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated high-density lipoprotein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated lipase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated triglycerides</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated gammaglobulin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevated transaminases</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevation of creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Elevation of gamma-glutamyl transferase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>High cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hormonal imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased low-density lipoprotein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased C-Reactive Protein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased average corpuscular haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased gamma-glutamyl transferase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased rheumatoid factor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased serum glutamate-pyruvate transaminase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased urea in blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased Hepatitis B viral load</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Increased vertical sleeve gastrectomy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Low folic acid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Negative tuberculosis test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Positive antinuclear antibodies</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Positive cutaneous tuberculosis test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Positive lupus anticoagulant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Positive tuberculosis test</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Decompensated diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Deficit of vitamin B12</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus Type-2</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Achilles tendinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Ankle pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Arm pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Articular inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Bone oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Cervical pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Cervicalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dorsalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Enthesitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Foot pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Gonalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Heel pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Heel spur</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Herniated disc</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Joint paint with involvement of the lower leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Leg pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Lower back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Navicular fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Osteoarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Osteoarticular pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pain in hand</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pain in lower limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Painful knees</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Psoriatic arthopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Psoriatic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Sore left arm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Sprained ankle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Stiffness in the morning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Stiffness of limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Tendinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Twisted and sprained feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Broken meniscus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Basocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Epidermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Infected sebaceous cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Thyroid node</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Tubular colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Compressive neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Epileptic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Paraesthesia in limbs</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Sciatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Throbbing headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Tingling sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Anxiety attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Decline</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Reduced sex drive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Worsening of depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Urination disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal menstruation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Epididimoorquitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Polymenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Allergic bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Asthmatic bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Obstructive sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pulmonary consolidation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Acute urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Cutaneous erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dishydrotic eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Eczema of the eyelids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Exacerbation of psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Facial rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Generalised rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Granulomatous lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Maculopapular rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Outbreak of psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Palmoplantar pustulosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Psoriasis guttata</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Psoriasis of the scalp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Telogen alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Worsening of psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Circumcision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Dental implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Extraction of wisdom tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Photocoagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Renal lithotripsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Root canal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Hypertension attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Raynaud’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Senile purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Information</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

